MLchartDataset catalogue

Recombinant human interleukin-11

Term · Oncology and biomedicine · MLC-T-ONC-007253

A drug used to increase the number of blood cells, especially platelets, in some cancer patients receiving chemotherapy. Recombinant human interleukin-11 is a form of interleukin-11 (a cytokine normally made by support cells in the bone marrow) that is made in the laboratory. It is a type of biological response modifier. Also called Neumega, oprelvekin, and rhIL-11.

Table 1. Record
IdentifierMLC-T-ONC-007253
FieldOncology and biomedicine
SynonymsNeumega; oprelvekin; rhIL-11
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-007253",
  "term": "Recombinant human interleukin-11",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to increase the number of blood cells, especially platelets, in some cancer patients receiving chemotherapy. Recombinant human interleukin-11 is a form of interleukin-11 (a cytokine normally made by support cells in the bone marrow) that is made in the laboratory. It is a type of biological response modifier. Also called Neumega, oprelvekin, and rhIL-11.",
  "synonyms": [
    "Neumega",
    "oprelvekin",
    "rhIL-11"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/recombinant-human-interleukin-11/"
}

Record 14,160 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.